Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05281471
Title Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Genelux Corporation
Indications

ovarian cancer

peritoneum cancer

fallopian tube cancer

Therapies

Bevacizumab + Carboplatin

Bevacizumab + Cisplatin

Bevacizumab + Carboplatin + GL-ONC1

Bevacizumab + Cisplatin + GL-ONC1

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.